Loading…
Sagimet Biosciences Inc. is projected to rise to $8.82 by 2027, a +20% move from its current price of $7.35. SGMT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $7.14 | $7.35 | $7.57 | +0.04% |
| Jul 13 | $7.06 | $7.36 | $7.66 | +0.08% |
| Jul 14 | $7.00 | $7.36 | $7.73 | +0.12% |
| Jul 15 | $6.95 | $7.36 | $7.80 | +0.16% |
| Jul 16 | $6.91 | $7.36 | $7.85 | +0.20% |
| Jul 17 | $6.87 | $7.37 | $7.91 | +0.24% |
| Jul 18 | $6.83 | $7.37 | $7.95 | +0.28% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.83 | $7.37 | $7.95 | +0.28% |
| Week 2 | $6.64 | $7.39 | $8.23 | +0.56% |
| Week 3 | $6.50 | $7.41 | $8.46 | +0.84% |
| Week 4 | $6.38 | $7.43 | $8.66 | +1.13% |
| Week 5 | $6.29 | $7.45 | $8.84 | +1.41% |
| Week 6 | $6.20 | $7.47 | $9.01 | +1.69% |
| Week 7 | $6.13 | $7.50 | $9.17 | +1.98% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company that develops novel therapeutics called fatty acid synthase (FASN) inhibitors for diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.
Sagimet also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc.
in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Sagimet Biosciences Inc. - Series A (SGMT) is a clinical-stage biopharmaceutical company focused on fatty acid synthase (FASN) inhibitors to treat metabolic dysfunction and fibrotic pathways. The stock currently trades at $7.79 per share and carries a market cap of $435.97M, with a rank of 5455.
The current price and market position place it among smaller-cap names in the sector. The forecasted path shows notable upward potential across multiple years, with the 2026 average price at $7.79 and rising to higher levels in subsequent years, culminating in large long-term upside. The projected average price by 2030 is $15.26 and by 2050 is $88.38, accompanied by substantial ROI growth through 2050.
A major floor 38.1% below — a decisive break under it would weaken the trend.
The nearest floor, 14.3% below — buyers have tended to step in here.
The nearest ceiling, 6.0% above — a clean break opens room to run.
A major ceiling 19.0% above — clearing it would confirm fresh momentum.
Key SGMT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SGMT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $7.52 | Sell | $7.45 | Sell |
| MA 10 | $7.52 | Sell | $7.40 | Sell |
| MA 20 | $7.10 | Buy | $7.25 | Buy |
| MA 50 | $7.20 | Buy | $6.99 | Buy |
| MA 100 | $6.38 | Buy | $6.72 | Buy |
| MA 200 | $6.58 | Buy | $6.52 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.25 | Neutral |
| Stoch RSI (14) | 20.66 | Neutral |
| CCI (20) | 41.78 | Neutral |
| Williams %R (14) | -45.16 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | 4.39 | Buy |
| Bollinger %B (20,2) | 0.64 | Neutral |
| Stochastic %K (14) | 54.84 | Neutral |
| TRIX (15) | 0.28 | Buy |
| Awesome (5,34) | 0.48 | Buy |
| Ultimate (7,14,28) | 43.19 | Neutral |
| Momentum (10) | 0.51 | Buy |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 7.39 | Sell |
| ADX (14) | 14.86 | Neutral |
| ATR (14) | 0.17 | Info |
The 30-day technical picture remains bullish on a near-term horizon. The RSI(14) is at 70, indicating strong momentum, while the 50-day simple moving average sits at $7.07 and the 200-day moving average at $6.54, suggesting near-term support around the mid-$6s and resistance near the current price level. A near-term floor is identified at $6.30 and an immediate ceiling at $7.79.
The 30-day price range spans from $6.21 to $9.78, highlighting upside potential above the resistance zone on a momentum read. Annualized volatility sits at 70%, underscoring elevated but survivable price swings in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.55 | $7.35 | $10.05 | 0% | Neutral | |
| $6.99 | $8.82 | $11.81 | +20% | Bullish | |
| $6.97 | $9.06 | $12.60 | +23% | Bullish | |
| $8.33 | $11.11 | $15.92 | +51% | Bullish | |
| $9.86 | $13.43 | $19.75 | +83% | Bullish | |
| $11.68 | $16.22 | $24.38 | +121% | Bullish | |
| $13.48 | $19.08 | $29.25 | +160% | Bullish | |
| $13.29 | $19.13 | $29.87 | +160% | Bullish | |
| $14.37 | $21.03 | $33.38 | +186% | Bullish | |
| $15.66 | $23.28 | $37.52 | +217% | Bullish | |
| $24.23 | $38.72 | $66.53 | +427% | Bullish | |
| $40.36 | $73.05 | $137.75 | +894% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $4.55 | $7.35 | $8.81 | +0.00% |
| August 2026 | $6.43 | $7.60 | $9.24 | +3.46% |
| September 2026 | $6.40 | $7.62 | $9.37 | +0.24% |
| October 2026 | $6.26 | $7.51 | $9.32 | -1.50% |
| November 2026 | $6.40 | $7.71 | $9.65 | +2.73% |
| December 2026 | $6.58 | $7.97 | $10.05 | +3.30% |
Click any year to see its month-by-month SGMT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Sagimet Biosciences Inc.'s 2026 outlook centres on $7.35, within a $4.55 to $10.05 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, SGMT could reach as high as $11.81, with a base case around $8.82 and support toward $6.99 — roughly +20% from $7.35. Buyers look set to stay in control over this stretch.
Expect SGMT to range from $6.97 to $12.60 through 2028. The $9.06 average target implies a +23% move from current prices. That is up +3% on the projected 2027 average. Momentum favours further upside here.
The SGMT price prediction for 2029 points to an average of $11.11 (low $8.33, high $15.92) — a potential gain of +51% on today's $7.35. Buyers look set to stay in control over this stretch.
In 2030, SGMT is projected to trade between $9.86 and $19.75, averaging $13.43 — a potential gain of +83% from today's $7.35. That is up +21% on the projected 2029 average. Momentum favours further upside here.
Sagimet Biosciences Inc.'s 2031 outlook centres on $16.22, within a $11.68 to $24.38 range. That is up +21% on the projected 2030 average. That marks a +121% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, SGMT could reach as high as $29.25, with a base case around $19.08 and support toward $13.48 — roughly +160% from $7.35. Momentum favours further upside here.
Expect SGMT to range from $13.29 to $29.87 through 2033. The $19.13 average target implies a +160% move from current prices. That is up 0% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The SGMT price prediction for 2034 points to an average of $21.03 (low $14.37, high $33.38) — a potential gain of +186% on today's $7.35. Momentum favours further upside here.
In 2035, SGMT is projected to trade between $15.66 and $37.52, averaging $23.28 — a potential gain of +217% from today's $7.35. That is up +11% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Sagimet Biosciences Inc.'s 2040 outlook centres on $38.72, within a $24.23 to $66.53 range. That is up +66% on the projected 2035 average. That marks a +427% change versus current levels. Momentum favours further upside here.
By 2050, SGMT could reach as high as $137.75, with a base case around $73.05 and support toward $40.36 — roughly +894% from $7.35. Buyers look set to stay in control over this stretch.
Investing $1,000 in SGMT today (≈ 136.054422 SGMT) could be worth
$9,938.5
+$8,938.5 (+894%) by 2050 · US Dollar
Based on the average projected SGMT price of $73.05 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SGMTwould be worth at today's price.
$1,000 invested in SGMT on Jul 10, 2025 (≈ 100.908175 SGMT) would be worth
$741.68
-$258.32 (-25.8%) today · 0.74× · US Dollar
Based on a SGMT entry price of $9.91 vs. today's $7.35.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.61 | $965.83 | -3.4% |
| 1 month ago | $6.5 | $1,130.77 | +13.1% |
| 3 months ago | $5.3 | $1,386.79 | +38.7% |
| 6 months ago | $6.24 | $1,177.88 | +17.8% |
| 1 year ago | $9.91 | $741.68 | -25.8% |
| All time (3.0y) ago | $15.95 | $460.82 | -53.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SGMT forecast.
Our base-case forecast reaches $15.00 around 2031.
Implied market cap at $15.00: $917.76M
The multi-year forecast paints a bullish trajectory with rising average prices and compounding upside. In 2026 the average price is $7.79 with an ROI of 0% and neutral sentiment, expanding in 2027 to an average of $9.39 (ROI 20.6%) and continuing higher through 2035. By 2030, the average is projected at $15.26 with a 95.9% ROI and bullish sentiment, followed by substantial gains to 2040 (average $47.22, ROI 506.2%) and 2050 (average $88.38, ROI 1034.6%), both with bullish sentiment.
These figures imply meaningful upside from the current level over the coming years, but they are estimates and not guarantees. The forecast shows a persistent bullish posture across the long horizon, with higher potential outcomes in later years balanced by inherent market and execution risks.
Tap a question to reveal the answer.
2030 average price is $15.26, with a min of $10.79 and a max of $23.39; ROI is 95.9% and sentiment is BULLISH.
The forecast shows bullish sentiment in multiple years with rising averages—reaching $15.26 by 2030 and $88.38 by 2050—alongside increasing ROI (e.g., 2030 95.9%, 2040 506.2%, 2050 1034.6%). These are estimates, not guarantees.
Yes. The 2050 maximum forecast is $179.32, which surpasses $100, illustrating potential upside under the provided projections.
Current price is $7.79 and market cap is $435.97M.
The 30-day range is $6.21 to $9.78, with RSI(14) at 70, SMA50 at $7.07, SMA200 at $6.54, support at $6.30, and resistance at $7.79; annualized volatility is 70%.
Sagimet Biosciences Inc. Community Discussion
0Share your Sagimet Biosciences Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.